SCHEMBL1103056

SCHEMBL1103056

c1ccc(-c2c3ccccc3c(-c3ccc4c(c3)c3ccccc3n4-c3ccccc3)c3cccnc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ATM Q13315 1/20 0.46
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPY5R Q15761 3/20 0.36
PTGER4 P35408 1/20 0.35
IL1R1 P14778 1/20 0.35
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
PDE4A P27815 3/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
FEN1 P39748 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
LOXL3 P58215 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102923 0.97 L3MBTL1 (0.49) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL411647 0.86 L3MBTL1 (0.62) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL24663115 0.85 L3MBTL1 (0.60) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL18624828 0.85 L3MBTL1 (0.60) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL15945583 0.84 KDM4E (0.51) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL13761684 0.83 L3MBTL1 (0.58) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL36307 0.83 L3MBTL1 (0.58) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL13761640 0.83 L3MBTL1 (0.58) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL262501 0.83 L3MBTL1 (0.58) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL13761683 0.83 L3MBTL1 (0.58) L3MBTL1KDM4EATMKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 L3MBTL1 1629/4885KDM4E 3367/4885ATM 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.